This cancer drug stock could double as its treatment hits the market, JPMorgan says
The investment bank initiated coverage with an overweight rating.
We haven't written up this one. CNBC has the full story — the link below goes straight to it.
More in Finance & Markets
Which International ETF Is the Better Buy: Schwab's Developed Markets SCHF or iShares' Emerging Markets IEMG?
SCHF offers lower fees and higher dividend yield, while IEMG provides concentrated emerging-market exposure with stronger 1-year returns.
EBID secures Moody’s credit rating upgrade, moves closer to investment grade
The ECOWAS Bank for Investment and Development (EBID) has secured a major credit rating upgrade from Moody’s Ratings, with the international agency raising the bank’s long-term issuer rating from B2…
BREAKING: FMDQ turnover hits N426.51 trillion in seven months as OMO, FX drive activity
The FMDQ Exchange recorded N426.51 trillion ($310.18 billion) in total market turnover between January and July 2026, driven by strong activity in foreign exchange transactions, Open Market Operations…
Bloomberg Surveillance 8/18/2026
Jonathan Ferro, Lisa Abramowicz and Annmarie Hordern speak daily with leaders and decision makers from Wall Street to Washington and beyond.
